Objective: To evaluate the effects of four weeks of ®sh oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Design and subjects: Very low density lipoprotein (VLDL) apolipoprotein B100 (apoB100) kinetics in ten healthy, white males, aged 22±43 y (mean 32 y) were investigated using a 13 C-leucine technique and gas chromatography-mass spectrometry before and after ®sh oil supplementation. Intervention: All subjects received 10 g (1.8 g EPA, 1.2 g DHA)ad of ®sh oil concentrate for four weeks. Results: Fish oil supplementation resulted in a decrease of total plasma VLDL (mean AE s.d. 1.11 AE 0.41 vs 0.87 AE 0.28 mmolal, P`0.05) and triacylglycerol concentrations (0.74 AE 0.27 vs 0.48 AE 0.21 mmolal, P`0.01). VLDL apoB100 pool size was decreased without alteration of the fractional synthetic rate but a signi®cant decrease of apoB100 production (2.23 AE 0.90 vs 1.54 AE 0.52 mgadlah, P`0.02). Following ®sh oil supplementation plasma concentrations of glucose and insulin as well as lipoprotein and hepatic lipase activities were unchanged. Fasting plasma concentrations of non-esteri®ed fatty acid (NEFA) were decreased (0.45 AE 0.12 vs 0.33 AE 0.10 mmolal, P`0.05). Conclusions: Dietary supplementation with ®sh oil in healthy males results in decreased VLDL-triacylglycerol concentrations through a decrease in VLDL particle synthesis. The decrease in NEFA substrate supply also contributes. Sponsorship: Fish oil (Maxepa
Introduction
Several epidemiological studies have revealed an inverse relationship between ®sh oil consumption and the incidence or mortality of coronary heart disease (CHD) (Norell et al, 1986; Gibson, 1988; Berg-Schmidt et al, 1993) . The bene®cial effects of ®sh oil are related to their content of long chain n-3 polyunsaturated fatty acids (n-3 PUFA) (Nordoy et al, 1994) .
The effects of n-3 PUFA on lipid metabolism are complex. A constant ®nding is a dose-dependent decrease in triacylglycerol (TG) plasma concentrations (Harris, 1989) . Plasma concentrations of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) typically tend to increase following high doses of ®sh oil (10 gad) (Harris, 1989; Mori et al, 1994) . However, contradicting responses have also been reported, which may be explained by variations in the quantity and quality of dietary fat intake as well as plasma lipid concentrations (Harris, 1989) .
However any potential adverse effects of n-3 PUFA on cholesterol metabolism are reversed by a 30%-fat diet. Regular ®sh meals signi®cantly reduce plasma triacylglycerol concentrations and also reverse the fall of HDL cholesterol which is typically seen in subjects on a lowfat diet (Mori et al, 1994) .
The effects of ®sh oil on apolipoprotein B100 (apoB100) metabolism are not fully understood. ApoB100 production and pool size were reduced in two studies in which lipoprotein kinetics were studied using radiolabelled lipoproteins, where the production rate was obtained indirectly from the catabolic rate (Illingworth et al, 1984; Nestel et al, 1984) .
The aim of this study was to analyse the short term effects of a high dose ®sh oil supplementation on VLDL composition and apoB100 production, measured directly, in healthy, male subjects using stable isotope tracer.
Subjects and methods

Subjects
The study was approved by the St. Mary's Hospital Local Research Ethics Committee in accordance with the Helsinki Declaration of 1975 as revised in 1983. Written, informed consent was obtained from each subject. Ten healthy Caucasian, male volunteers, aged 22±43 y (mean 32 y) were included in the study. None of the subjects was on any medication or had any metabolic disorder.
Study design
Subjects received 10 g of ®sh oil concentrate (1.8 g eicosapentanoic acid, 1.2 g docosahexanoic acid) (Maxepa 1 , Seven Seas Ltd, Hull, England) daily for four weeks with no changes to their diet and physical activity. Dietary intake of each subject was recorded using food scales for 5 d before starting and during the last week of ®sh oil supplementation. Before and at the end of the four week trial the subjects came to the Metabolic Day Ward after an overnight fast for 12 h. At approximately 09.00 h a cannula was inserted into a dorsal vein of each hand; one cannula was used for the administration of L-[1-
13 C]leucine (99% 13 C, Cambridge Isotope Laboratories, Woburn, MA, USA) and the other for blood sampling. Following a priming dose (1 mgakg body weight) of the tracer, a constant infusion (1 mgakg body weightah) was commenced for 6 h. At the end of the infusion, a bolus of 100 Uakg body weight sodium heparin (C.P. Pharmaceuticals Ltd., Wrexham, UK) was given intravenously in order to measure lipoprotein and hepatic lipase activities. Subjects fasted throughout the study with only mineral water being allowed.
Blood samples (12 ml) were taken into EDTA tubes at 0 and 1 h and thereafter every 30 min throughout the infusion for VLDL apoB100 isolation and for plasma lipoproteins and NEFA concentrations at 0 h and 1 h. Plasma was immediately separated by low-speed centrifugation for 30 min at 4
C. An equal mixture (50ml) of 5% NaN 3 and 5% gentamycin was added to each of these plasma samples. Blood (5 ml) was taken into heparinized chilled tubes at times 0, 2 and 3 h and thereafter at 30 min intervals for the remainder of the infusion. The plasma was stored at 770 C for analysis of 13 C-enrichment of plasma a-keto isocaproic acid (aKIC), the deamination product of leucine. Blood (4 ml) was taken at 0, 2, 4 and 6 h for measurement of plasma lipids and glucose; insulin was measured at 0 and 6 h. Blood (5 ml) was taken into tubes without additives 15 min after the heparin injection to assess lipase activity.
VLDL and apoB100 separation and quanti®cation VLDL was separated by ultracentrifugation and tube slicing, and stored at 770 C for apoB100 isolation . A 0.6 ml aliquot was delipidated twice with centrifugation at 4 C and decantation of the supernatant, ®rstly by adding 24 ml of a 10:30 volavol mixture of methanol and diethyl ether and centrifugation for 10 min, and secondly by adding 6 ml of diethyl ether and centrifugation for 2 min. The precipitated protein was dried at 30 C in a fume cupboard, then reconstituted in 60 m l TRIS-buffer containing mercaptoethanol and glycerol, incubated at 100 C for 3 min and subjected to polyacrylamide gradient (5±16%) gel electrophoresis. After overnight electrophoresis, the gel was stained with Cromassie blue (0.5% in methanolaacetic acid solution) and destained for several hours . The apoB100 gel band was cut and transferred to 25 ml tubes with Te¯on 1 -lined screw caps (Phillip Harris Ltd, London, England). 2 ml of 6N HCl were added and the tubes sealed under nitrogen and incubated at 110 C for 24 h to completely hydrolyze the apoB100.
A known amount of norleucine, a non-physiological amino acid used as internal standard, was added to each sample. The amino acids were puri®ed by passing through a cationic resin column and derivatized as described previously . Brie¯y, plasma aKIC was reacted with pyridine and N,O-bis(trimethylsilyl)tri¯uoro-acetamide to form the O-trimethylsilylquinoxalinol derivative. Enrichment of both leucine and aKIC was quanti®ed by using a Finnigan INCOS XL mass spectrometer (MS) run in electron impact mode.
Quanti®cation of apoB100 ApoB100 in VLDL was estimated from the mean of samples taken at three time points in the study (0, 2 and 4 h) using an ELISA technique with antihuman apoB antiserum (Boehringer) and anti-sheep IgG alkaline conjugate (Sigma). ApoB calibration serum (Boehringer) was used for the calibration curve for each plate. The apoB100 content of VLDL aliquots was corrected for the plasma volume from which it had been derived.
Measurement of stable isotope enrichment
Selective ion monitoring of the derivatized samples at a mass to charge ratio (maz) of 302 for unlabelled norleucine and leucine and maz 303 for labelled leucine was used to determine isotopic abundance. The atom percent excess (APE) enrichment was calculated using the following formula
where IR t is the isotope ratio of the sample at time t, and IR 0 is the isotope ratio of sample at time zero. The enrichment of plasma aKIC values (precursor pool) was similarly obtained. Mole percent excess (MPE) was calculated from enrichment calibration curves that were derivatised and run with the study samples. This method of calculation is equivalent to the method of Cobelli et al, 1987 .
Calculation of apoB100 production Fractional synthetic rate (FSR) of VLDL apoB100 (as poolsah) was calculated from the rate of incorporation of 13 C-leucine into the circulating protein and application of monocompartmental kinetics and a monocompartmental model (Parhofer et al, 1991) At Ap1 À e ÀktÀd where A(t) is the traceratracee (labelledaunlabelled leucine) ratio at time t, Ap is the precursor traceratracee ratio (taken as the plasma aKIC enrichment), d is the delay time until the appearance of labelled apoB100 in the VLDL fraction and k represents the FSR of VLDL apoB100. The absolute production rate (APR) of VLDL apoB100 was calculated as: APR FSR (poolsah) 6 apolipoprotein pool size (mg)
Other assays Laboratory glucose measurements were performed by a glucose oxidase method. Insulin was determined with an ELISA method (Anyaoku & Johnston, 1995) . Cholesterol, triacylglycerol and NEFA were measured enzymatically using a centrifugal analyser (COBAS, Baker, Windsor, UK). HDL cholesterol was isolated by the dextran-sulphate MgC12 method and LDL cholesterol calculated with Friedewald's formula (Friedewald et al, 1972) . Plasma and VLDL apoB100 were measured by an ELISA technique using Boheringer antibodies and Nunc plates. Plasma lipase activity was quanti®ed on the basis of fatty acid release from a radiolabelled triolein substrate, and assessed by liquid scintillation counting (Baynes et al, 1991) .
Body impedance
Lean body mass (LBM) was assessed by using a body impedance meter (Bodystat 1500, Douglas, Isle of Man, UK), which measures bioelectrical impedance following a
Effects of ®sh oil supplementation P Bordin et al 50 Hz, 800 mA current through the body. LBM was calculated using standard equations with bioelectrical impedance, height and body weight (Houtkooper et al, 1996) . Lean body mass is expressed as a percentage of total body weight.
Statistical analyses
The mean and standard deviation were calculated for each parameter. Differences in the same individuals before vs after ®sh oil were examined by two tailed paired t-test. Data which were not normally distributed (insulin values) were log-transformed before analysis. These calculations and the monoexponential function for apoB kinetics were run with the Statistical Package for Social Sciences (SPSS 6.0 for Windows).
Results Table 1 summarises the characteristics of the subjects before begin of the study. Body mass index (before, mean AE s.d., 23.0 AE 2.4; after, 23.0 AE 2.5) and lean body mass (before, 83.8 AE 3.8; after, 83.9 AE 3.0%) remained constant during the study. Dietary energy intake did not alter, nor was there any alteration in intake of other fats during the study period. Fish oil was well tolerated and the compliance good. Three subjects experienced mild¯atu-lence, belching and mild epigastric discomfort. Table 2 shows the effects of ®sh oil on lipids, glucose, insulin and lipase values. There was a signi®cant decrease in plasma NEFA (27%, P`0.05) and total triacylglycerol (22%, P`0.05) concentrations due to a reduction in VLDL triacylglycerol. HDL cholesterol concentrations did not change signi®cantly and nor did total or LDL cholesterol. Lipid concentrations did not change over the 6 h infusion (data not shown). Hepatic and lipoprotein lipase activities were not modi®ed by ®sh oil. Blood glucose and insulin concentrations did not change signi®cantly.
VLDL apoB100 kinetics
Plasma aKIC 13 C-enrichment increased rapidly following the start of 13 C-leucine infusion, reaching a plateau by the second hour. The pattern was similar before and after ®sh oil. Enrichment of 13 C-leucine in the VLDL apoB100 demonstrated monoexponential kinetics (Figure 1 ). The enrichment plateau was reached at 5±6 h (MPE 5.01± 5.4% before and MPE 5.22±5.57% following ®shoil). The 13 C-leucine enrichment curve was shifted to the left following four weeks ®sh oil ingestion (Figure 1) . The observed apoB100 kinetic data are shown in Table 3 . There was no signi®cant change in FSR. The VLDL apoB100 pool size decreased after ®sh oil ingestion (43%, P`0.05). The apoB100 production rate was reduced (29%, P`0.05). The ratio of apoB100 to triacylglycerol (Table 4) did not change signi®cantly after ®sh oil; the ratio was unique to individual subjects.
Discussion
Fish oil has several effects on lipid metabolism, most notably a reduction of triacylglycerol concentrations due to diminished hepatic synthesis (Mackness et al, 1994; Eritsland et al, 1995) . Data on apoB kinetics are limited: Nestel et al, 1984 reported that ®sh oil supplementation reduced VLDL apoB synthesis using a radioisotopic technique. These studies have both practical and theoretical limitations: the use of radioactive tracer excludes certain groups of patients and makes repetitive studies on the same patient ethically dif®cult. Structural modi®cations of lipo- (range); NEFA non esteri®ed fatty acids, *P`0.05, **P`0.01; lipase activities are expressed as mmol of free fatty acid releasedahal of post heparin plasma; ***P`0.05 at 0 vs 6 h.
Effects of ®sh oil supplementation P Bordin et al proteins during their isolation andaor radiolabelling may alter their kinetics. Furthermore, synthetic rates are indirectly obtained from the measured catabolic rates assuming steady-state conditions throughout the study . These problems are overcome by using an intrinsic labelling technique (Waterlow et al, 1978) . We therefore employed a 13 C-leucine technique in which the incorporation rate of the stable isotope labelled aminoacid into VLDL apoB was measured. The validity of the method depends on certain assumptions : (a) there must be equilibrium between plasma and intrahepatic aKIC; (b) the level of plasma aKIC enrichment must re¯ect the enrichment of the direct precursor of apoB-100 (leucyl-RNA); (c) newly synthesized apoB is homogenously labelled and secreted. As some newly synthesized VLDL are degraded intracellularly, the production rate of apoB100 measured in turnover studies, either using endogenous (mass spectrometry) or exogenous labelling (radiolabelling) re¯ects not the level of absolute hepatic synthesis, but rather the level of secretion or appearance of apoB100 from the liver into the circulation. This is the ®rst time the effect of n-3 PUFA on VLDL apoB100 synthesis has been studied by direct measurement using a stable isotope approach. We chose a sample of healthy normolipidaemic people homogeneous for sex, age and race, who consumed a high dose (3 gad) of n-3 PUFA for four weeks, although control subjects without dietary (Demant et al, 1996; Thornton et al, 1996) . The reported coef®cient of variation was 10.5% (Thornton et al, 1996) . The most striking effect of n-3 PUFA observed was a decrease in VLDL apoB100 pool size (43%, P`0.05) and production rate (29%, P`0.05). This was observed without any change in BMI, lean body mass or diet. The results are similar to those observed by Nestel et al, 1984 who found a 73% decrease in pool size and a 55% decrease in production rate using a considerably higher dose of ®sh oil (up to 30% of daily energy needs). Hepatic and lipoprotein lipase activities did not change after n-3 PUFA supplementation, consistent with other studies (Desager et al, 1989; Bagdade et al, 1990) . Our own and other data therefore do not suggest a major alteration in VLDL catabolism. Previous studies have suggested that ®sh oil supplementation results in the production of small VLDL, with a reduced lipid content, which are rapidly converted to LDL (Harris, 1989; Berg-Schmidt et al, 1993) .
The hypotriacylglycerolemic effect of n-3 PUFA (22%) was almost exclusively due to the decrease of VLDL-TG (35%). A reduction in VLDL-C (750%) and plasma apoB100 was also observed in accordance with the literature (Nestel et al, 1984; Harris, 1989; Berg-Schmidt et al, 1993; Mori et al, 1994) . The reduction of VLDL apoB100 means a diminished number of circulating VLDL particles, given that each lipoprotein particle contains only one apoB100 molecule. In the present study the VLDL ratio of components apoB100 to triacylglycerol, was unaltered. Large inter-subject variation in VLDL composition were observed in the current study suggesting that this parameter may represent a unique statement of VLDL assembly in normolipidaemic individuals.
Although VLDL-TG and VLDL apoB100 decrease after ®sh oil supplementation, LDL-C did not change (or has even been reported to increase in hypertriacylglycerolemic subjects) (Nestel et al, 1984; Nenseter et al, 1992) . The absence of change of LDL-C in the present study re¯ects the small pool of VLDL relative to LDL in circulation. HDL cholesterol did not change signi®cantly in the present study and results in the literature are con¯icting (Rudel et al, 1991; Thornburg & Rudel, 1992) .
Conclusions
The signi®cant decrease in NEFA (27%, P`0.05) following ®sh oil supplementation has not been previously reported. Although the present study did not include control subjects, plasma NEFA concentrations decreased consistently in all subjects studied (individual data not shown), while dietary intake and the level of physical activity were unchanged. Samples for plasma NEFA concentrations have been collected under exactly the same conditions (fasting, day time, resting) before and after ®sh oil supplementation. It is therefore most likely that the decrease in plasma NEFA concentrations is secondary to ®shoil supplementation. This could be a factor in the TG decrease, limiting substrate supply for VLDL-TG synthesis. It may also re¯ect increased insulin sensitivity induced by ®sh oil, as hypothesized by some authors (Fasching et al, 1991) . In the present study there was no signi®cant change in basal insulin and glucose plasma concentrations, suggestive of increased insulin sensitivity. This is consistent with ®ndings recently reported in subjects with type II diabetes (McManus et al, 1996) .
